Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:HARP

Harpoon Therapeutics (HARP) Stock Price, News & Analysis

Harpoon Therapeutics logo

About Harpoon Therapeutics Stock (NASDAQ:HARP)

Key Stats

Today's Range
$23.01
$23.01
50-Day Range
$22.34
$23.01
52-Week Range
$3.11
$23.21
Volume
N/A
Average Volume
1.52 million shs
Market Capitalization
$389.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00
Consensus Rating
Hold

Company Overview

Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company at the forefront of revolutionizing cancer treatment and other diseases. The company is developing a novel T-cell engagers class to use the body's immune system to fight infection. 

Harpoon currently has several products in various stages of clinical trials, such as HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors and HPN217, which is in Phase I/II clinical trials for the treatment of multiple myeloma.

Shares of Harpoon have skyrocketed following the release of data from its Phase 1 clinical trial for HPN217, a single-agent candidate for pretreated patients with relapsed/refractory multiple myeloma (RRMM). The data showed clinical activity and a "tolerable safety profile," with low-grade CRS observed in 29% of patients following the first or second doses of the drug and no incidents of "Grade 3 or higher CRS." Analysts have a consensus price target of $8.75 on the stock, suggesting over 85% upside potential.

Harpoon has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products incorporating TriTAC platform technology and soluble T cell receptors. In addition, the company has a preclinical stage product, HPN601, for treating multiple solid tumor indications.

Harpoon Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
16th Percentile Overall Score

HARP MarketRank™: 

Harpoon Therapeutics scored higher than 16% of companies evaluated by MarketBeat, and ranked 919th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Harpoon Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Harpoon Therapeutics has received no research coverage in the past 90 days.

  • Read more about Harpoon Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Harpoon Therapeutics are expected to decrease in the coming year, from ($1.49) to ($4.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Harpoon Therapeutics is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Harpoon Therapeutics is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Harpoon Therapeutics has a P/B Ratio of 14.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for HARP.
  • Dividend Yield

    Harpoon Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Harpoon Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for HARP.
  • Search Interest

    1 people have searched for HARP on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Harpoon Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.00% of the stock of Harpoon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    74.01% of the stock of Harpoon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Harpoon Therapeutics' insider trading history.
Receive HARP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HARP Stock News Headlines

Crypto Crash Ahead? (27 Experts Weigh In)
Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!
T-cell targeting Candid Therapeutics launches with $370m
See More Headlines

HARP Stock Analysis - Frequently Asked Questions

Harpoon Therapeutics, Inc. (NASDAQ:HARP) issued its earnings results on Monday, March, 27th. The company reported ($5.50) earnings per share for the quarter, missing the consensus estimate of ($4.70) by $0.80. The firm earned $4.09 million during the quarter, compared to the consensus estimate of $11.06 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 893.55% and a negative net margin of 81.68%.

Shares of Harpoon Therapeutics reverse split before market open on Tuesday, September 5th 2023. The 1-10 reverse split was announced on Tuesday, September 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Harpoon Therapeutics (HARP) raised $76 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Harpoon Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

Last Earnings
3/27/2023
Today
11/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:HARP
Fax
N/A
Employees
53
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.00
High Stock Price Target
$23.00
Low Stock Price Target
$23.00
Potential Upside/Downside
0.0%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-67,730,000.00
Pretax Margin
-81.67%

Debt

Sales & Book Value

Annual Sales
$37.34 million
Book Value
$1.63 per share

Miscellaneous

Free Float
14,054,000
Market Cap
$389.61 million
Optionable
Optionable
Beta
2.11
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:HARP) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners